Clinical trials: Psoriasis Patients
Inflammatory Joint Diseases, Rheumatoid Arthritis (RA)
Oxidative Stress in Autoimmune Rheumatic Diseases
Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus…
- Conditions
- Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS)
- Trial name
- REDOX-ARD (NCT07536529)
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- University of Thessaly
Psoriasis Vulgaris
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients…
- Trial name
- NCT01465282
- Testing
- CT327 0.05%, CT327 0.1%, CT327 0.5%
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 160 people
- Sponsor
- Creabilis SA
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Crohn's Disease
The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and…
- Conditions
- Rheumatoid Arthritis, Crohn's Disease, Ankylosing Spondylitis, Psoriasis
- Trial name
- NCT00224562
- Testing
- TNF-alpha antagonists
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Arthritis, Psoriatic
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
This is a multicenter, prospective, non-interventional, observational single arm study. 100 patients will be recruited in the Netherlands over a one year period.
- Trial name
- REWARD (NCT02875184)
- Where
- 21 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Amgen
Plaque Psoriasis
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
Psoriasis (PsO) is a systemic immune disease that affect 2-4% of the population worldwide. PsO causes tremendous burden in terms of quality of life, psychological impact, disability and work productivity of affected individuals.
- Trial name
- NCT04537689
- Testing
- Ixekizumab, Methotrexate, Cyclosporin A
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Singapore General Hospital
Rheumatoid Arthritis, Psoriatic Arthritis
PBR28 PET and Inflammatory Arthritis
The importance of the detection of early inflammatory arthritis is recognised as being essential to the prevention of permanent joint damage.
- Trial name
- NCT02361385
- Testing
- this is not an interventional study
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- University of Oxford
Moderate to Severe Psoriasis
Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing
JS005-002 is a randomized, double-blinded, placebo-controlled phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of multiple doses of JS005 (recombinant humanized anti-IL-17A…
- Trial name
- NCT05344248
- Testing
- JS005 (recombinant humanized monoclonal antibody against IL-17A)
- Where
- 22 sites in China
- Volunteers
- 183 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Psoriasis, Obesity
The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients
The purpose of this study is to evaluate the effect that weight loss has on the severity of psoriasis in obese subjects. Fifty obese (BMI equal to or greater than 30) patients with moderate to severe plaque psoriasis will be…
- Trial name
- NCT01137448
- Testing
- Weight Loss
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Psoriatic Arthritis
Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis
An abnormal intestinal microbiota may be the mediator of the common inflammatory pathways seen in psoriatic arthritis. This study will explore clinical aspects associated with modifying the intestinal microbiota by infusing fecal…
- Trial name
- FLORA (NCT03058900)
- Testing
- Fecal microbiota transplantation (FMT), Methotrexate (MTX)
- Where
- 2 sites in Denmark
- Volunteers
- 31 people
- Sponsor
- Odense University Hospital
Psoriasis
A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis
This trial is a Phase IIa clinical trial. Around 65 subjects will be enrolled into this study to primarily assess the treatment efficacy of 5% GM-XANTHO in patients with psoriasis, as well as the safety and tolerability of 5%…
- Trial name
- NCT06620692
- Testing
- 5% GM-XANTHO [GM-XAN003]
- Volunteers
- 65 people
- Sponsor
- Xantho Biotechnology Co., LTD
Psoriasis
Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain
Observational, prospective and multicenter study in approximately 30 sites nationwide. The investigators participating in this study will be dermatologists specializing in this pathology.
- Trial name
- APPROPIATE (NCT03539419)
- Where
- 58 sites in Spain
- Volunteers
- 153 people
- Sponsor
- Amgen
Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
- Trial name
- BDS1307 (NCT02070965)
- Testing
- DFD01 Spray, Comp01 Lotion
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis, Cardiovascular Diseases
The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis
Psoriasis vulgaris is no longer considered as a chronic inflammatory disease restricted to the skin. Evidence has accumulated in the past that psoriasis is a chronic inflammatory systemic disease.
- Conditions
- Psoriasis, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- CASTIP (NCT01088165)
- Testing
- Adalimumab treatment arm, Fumaric acid esters treatment group, Narrow band UVB radiation
- Where
- Austria
- Volunteers
- 66 people
- Sponsor
- Medical University of Vienna
Psoriasis
An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Given the role of IL-17 in the development of entheseal-driven pathology, a therapeutic strategy aimed at blocking IL-17 would be a logical option for the treatment of subclinical enthesitis in psoriasis patients.
- Trial name
- INTERCEPT (NCT04488185)
- Testing
- Secukinumab 300 mg
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)
- Trial name
- NCT00306878
- Testing
- Abatacept
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic…
- Trial name
- RESPONSE (NCT00096928)
- Where
- 182 sites in United States
- Volunteers
- 1,846 people
- Sponsor
- Genentech, Inc.
Inflammatory Arthritis, Spondylarthropathies
Assessing Pain by the painDETECT Questionnaire (PDQ)
Prospective cohort study using drug survival rates to assess the predictive value of the PDQ when used to classify patients into a non-neuropathic pain phenotype group (score <13) or a neuropathic pain phenotype group (score ≥13)
- Conditions
- Inflammatory Arthritis, Spondylarthropathies, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- NCT06402396
- Testing
- bDMARDS
- Volunteers
- 7,056 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Psoriasis
Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis
Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.
- Trial name
- NCT02918123
- Testing
- FURESTEM-CD Inj.
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Chronic Plaque-type Psoriasis
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with…
- Trial name
- NCT07844772
- Testing
- IL-17 Inhibitor Therapy, Conventional Systemic Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul Training and Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.